Stifel Nicolaus reiterated their hold rating on shares of Dechra Pharmaceuticals plc (LON:DPH) in a research note released on Tuesday, July 11th. Stifel Nicolaus currently has a GBX 1,550 ($20.45) price objective on the stock.

Several other equities research analysts also recently issued reports on the company. Investec restated a buy rating and issued a GBX 1,840 ($24.27) price target on shares of Dechra Pharmaceuticals plc in a report on Thursday, July 6th. N+1 Singer restated a buy rating and issued a GBX 1,666 ($21.98) price target on shares of Dechra Pharmaceuticals plc in a report on Thursday, July 6th. Numis Securities Ltd restated an add rating and issued a GBX 1,890 ($24.93) price target on shares of Dechra Pharmaceuticals plc in a report on Thursday, July 6th. Panmure Gordon restated an under review rating on shares of Dechra Pharmaceuticals plc in a report on Thursday, April 20th. Finally, Royal Bank Of Canada increased their price target on Dechra Pharmaceuticals plc from GBX 1,630 ($21.50) to GBX 1,890 ($24.93) and gave the stock an outperform rating in a report on Tuesday, March 14th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Dechra Pharmaceuticals plc has an average rating of Buy and a consensus target price of GBX 1,648.71 ($21.75).

Shares of Dechra Pharmaceuticals plc (LON:DPH) traded up 1.08% on Tuesday, reaching GBX 1780.00. 49,430 shares of the company were exchanged. The company has a 50-day moving average price of GBX 1,746.80 and a 200 day moving average price of GBX 1,686.03. The stock’s market capitalization is GBX 1.65 billion. Dechra Pharmaceuticals plc has a 1-year low of GBX 1,189.00 and a 1-year high of GBX 1,970.00.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/07/dechra-pharmaceuticals-plc-londph-receives-hold-rating-from-stifel-nicolaus-updated-updated-updated.html.

In related news, insider Ian Page sold 134,500 shares of the stock in a transaction that occurred on Wednesday, June 21st. The stock was sold at an average price of GBX 1,927 ($25.42), for a total transaction of £2,591,815 ($3,418,829.97).

About Dechra Pharmaceuticals plc

Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development.

Analyst Recommendations for Dechra Pharmaceuticals plc (LON:DPH)

Receive News & Stock Ratings for Dechra Pharmaceuticals plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals plc and related stocks with our FREE daily email newsletter.